Crucell Announces PER.C6® Licensing Agreement with Tibotec
Dutch biotechnology company Crucell N.V. announced that it has signed a PER.C6® license agreement with Ireland-based Tibotec Pharmaceuticals Ltd. The non-exclusive agreement allows Tibotec to use the PER.C6® cell line for research in the field of virology.
Under the terms of the agreement, Tibotec will pay a research license fee, annual maintenance fees and milestone payments. Further financial details were not disclosed.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.